Leadership Team

A highly experienced team with a strong track record of performance

The ImmVirX team comprises key directors and the executive and scientific staff from Viralytics, a clinical-stage oncolytic virus company acquired in June 2018 by Merck and Co. Inc. for A$502 million.

Board

Malcolm McColl

Dr Malcolm McColl

Co-Founder and Acting Chairman

Prof. Darren Shafren

Prof. Darren Shafren

CSO and Co-Founder

Dr Leonard Post

Dr Leonard Post

Non-Executive Director

Robert Routley

Mr Robert Routley

Jeannie Joughlin

Dr Jeannie Joughin

Non-Executive Director

In the News

View our recent news stories

Discover the latest news articles featuring ImmVirX, including research innovations, stories about our people and reports from the latest events.

View All Stories

Oksana Zdanska

ImmVirX appoints Dr. Oksana Zdanska as Medical Director

April 16, 2024 No Comments

ImmVirX and Innovent Enter into Clinical Trial Collaboration to Investigate the Combination of IVX037 and Sintilimab in Difficult-to-treat Cancers

February 21, 2024 No Comments

R and D

ImmVirX receives $3.77M R&D tax refund for FY23

February 12, 2024 No Comments